GlassScriptPhysician profile
Timothy J Grenemyer
NPI 1588699391
$9,713.02
in general payments reported to CMS, 2019-2025
38 companies · $2,819 in 2025
The $2,819 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $211 · 2021: $220 · 2022: $1,551 · 2023: $2,143 · 2024: $2,459 · 2025: $2,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,391 · Education: $29.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,390.73 |
| Education | $29.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,278.60 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,245.35 | 2022-2025 | |
| Lilly USA, LLC | $986.85 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Aimmune Therapeutics, INC. | $654.00 | 2024-2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $543.51 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Insulet Corporation | $523.06 | 2022-2023 | Omnipod |
| Glaxosmithkline, LLC. | $498.52 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $393.59 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $361.52 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.31 | 2019-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $329.03 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $312.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $294.09 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $246.19 | 2022-2025 | |
| Mylan Specialty L.P. | $194.86 | 2024 | Yupelri |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $186.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.67 | 2023-2025 | Caplyta |
| Viatris Specialty LLC | $138.48 | 2025 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $136.99 | 2022 | |
| Astellas Pharma US INC | $126.82 | 2024-2025 | Veozah |
| Horizon Therapeutics Plc | $106.89 | 2022-2023 | Tepezza |
| Allergan, INC. | $97.98 | 2020 | |
| Lundbeck LLC | $80.94 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $74.11 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.71 | 2023-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $59.17 | 2022-2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $43.75 | 2022-2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $30.35 | 2021-2022 | |
| Exeltis, USA INC. | $29.68 | 2025 | Slynd |
| Neurocrine Biosciences, INC. | $22.91 | 2025 | |
| Seqirus USA INC | $22.66 | 2025 | Flucelvax, Fluad |
| Xeris Pharmaceuticals, INC. | $21.70 | 2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $20.48 | 2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $20.04 | 2022 | |
| Tactile Systems Technology INC | $19.18 | 2025 | Nimbl, Flexitouch Plus |
| Alkermes, INC. | $16.00 | 2020 | |
| Axonics, INC. | $15.63 | 2022 | |
| Merck Sharp & Dohme LLC | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Grenemyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.